Skip to main content
. 2022 Jul 25;12:12691. doi: 10.1038/s41598-022-16727-w

Table 4.

Summary of the subgroup analyses of the correlation between NLR and DFS in CCA patients.

Subgroup Number of studies HR [95%CI] P value Heterogeneity
I2 p
Cancer type
CCA* 1 1.43 [1.05–1.96] 0.02 - -
ICCA 10 1.44 [1.17–1.77]  < 0.01 73%  < 0.01
ECCA 3 1.11 [0.68–1.83] 0.67 70% 0.03
Treatment
Surgery 11 1.40 [1.13–1.74]  < 0.01 78%  < 0.01
Non-surgery 4 1.42 [1.15–2.75]  < 0.01 0% 0.78
Cut-off value
NLR > 3 6 1.56 [1.04–2.34] 0.03 84%  < 0.01
NLR ≤ 3 9 1.33 [1.10–1.62]  < 0.01 59% 0.01
Region
Eastern 11 1.36 [1.15–1.61]  < 0.01 62%  < 0.01
Western 4 1.72 [0.81–3.63] 0.16 88%  < 0.01
Sample size
 ≥ 200 6 1.34 [1.13–1.59]  < 0.01 21% 0.28
 < 200 9 1.44 [1.11–1.88]  < 0.01 79%  < 0.01
Age**
 ≥ 60 4 1.70 [1.23–2.34]  < 0.01 24% 0.26
 < 60 11 1.30 [1.08–1.57] 0.01 74%  < 0.01

*Includes both ICCA and ECCA. **Mean/median age of the study cohort. ECCA extrahepatic cholangiocarcinoma, HR hazard ratio, ICCA intrahepatic cholangiocarcinoma, NLR neutrophil-to-lymphocyte ratio.